Lupin rises as arm receives USFDA approval for Generic Plan B Tablets

25 Jan 2013 Evaluate

Lupin is currently trading at Rs. 590.05, up by 0.90 points or 0.15% from its previous closing of Rs. 589.15 on the BSE.

The scrip opened at Rs. 592.00 and has touched a high and low of Rs. 594.10 and Rs. 590.05 respectively. So far 2,205 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 631.90 and a 52 week low of Rs. 412.15.

The current market cap of the company is Rs. 26,392.00 crore.

The promoters holding in the company stood at 46.85% while Institutions and Non-Institutions held 43.40% and 9.75% respectively.

Pharma major, Lupin’s subsidiary - Lupin Pharmaceuticals Inc (collectively Lupin) has received final approval for its Levonorgestrel Tablets USP, 0.75 mg (Rx/OTC) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharmaceutical Products R&D, Inc.’s Plan B Tablets, 0.75 mg.

Lupin’s Levonorgestrel Tablets Levonorgestrel 0.75mg tablets is a progestin?only emergency contraceptive, indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure.

Plan B Tablets had annual US sales of approximately $81.1 million (IMS MAT Sept 2012 sales).

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×